|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
However, preferential use of unmutated IGHV genes was unique to Boxers with CLL, suggesting Boxers may be a valuable model to investigate unmutated CLL.
|
29385200 |
2018 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
<i>COBLL1</i> serves as an independent molecular marker for overall survival in chronic lymphocytic leukemia patients with unmutated IGHV.
|
29122990 |
2018 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
The specific quantification of endogenous LPL protein correlates with mRNA expression levels and mutational IGHV status, suggesting LPL protein as a possible reliable prognostic marker in CLL.
|
29953583 |
2018 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, we observe that non-coding mutations in IGHV-mutated CLLs are enriched in H3K27ac-associated regulatory elements outside accessible chromatin.
|
29785028 |
2018 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Altogether, our results show that a combination of normal SPE and mutated IGHV genes defines a subgroup of patients with CLL who evolve very slowly and who might never need treatment.
|
29745034 |
2018 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, IGHV mutational status shows prognostic impact in CLL patients with good prognosis genomic features.
|
28641468 |
2018 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Importantly, we confirmed by multivariate analysis that this was independent of IgHV mutational status or subset #2 stereotyped receptor (<i>P</i> < 0.0001).<b>Conclusions:</b> We have demonstrated for the first time that a light chain can affect CLL prognosis and that IgLV3-21 light chain usage defines a new subgroup of CLL patients with poor prognosis.<i></i>.
|
29945996 |
2018 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
The reasons for this difference are still unclear, but it has been noted that particular IGHV genes associate with U-CLL vs M-CLL.
|
28125682 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The expression of several genes correlates closely with the IGHV mutational status and could be used to assess prognosis in CLL.
|
27185377 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.
|
27890932 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Taking advantage of a population of 406 untreated Chinese patients with CLL at early and advanced stage of disease, we identified the strongest prognostic markers of TTFT and, subsequently, in a cohort of 173 patients who had complete data for all 3 variables, we integrated the data of traditional staging system, cytogenetic aberrations, and mutational status of immunoglobulin heavy chain variable region (IGHV) in CLL-PI.
|
28091403 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
PosttranslationalModification |
BEFREE |
In T-cell lymphomas, anaplastic large-cell lymphoma is defined by mutually exclusive rearrangements of <i>ALK</i>, <i>DUSP22/IRF4</i>, and <i>TP63</i> Genetic alterations affecting <i>TP53</i> and the mutational status of the immunoglobulin heavy-chain variable region are important in clinical management of chronic lymphocytic leukemia.
|
28600336 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
On a cohort of 110 patients with CLL treated with first-line fludarabin, cyclophosphamide, and rituximab treatment compared with 33 untreated (watch and wait) patients with CLL, we report more frequent complex karyotypes (34 vs 15%; P = .05), unmutated IGHV (70 vs 21%; P < .0001), ATM deletion (25 vs 6%, P = .02), and NOTCH mutation (3 vs 17%, P = .04).
|
27678008 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Bootstrap univariate Cox regression analysis confirmed that HIF1A mRNA overexpression is a significant unfavorable prognosticator in CLL (hazard ratio=3.75, bias-corrected and accelerated 95% confidence interval=1.43-24.36, bootstrap p<0.001), independent of other established prognostic factors, including CD38 expression, the mutational status of the immunoglobulin heavy chain variable region (IGHV), and the clinical stage (Binet or Rai stage) or risk group (p<0.001 in all cases).
|
28038356 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
MYD88-mutated CLL formed a prognostically favorable subset with a high frequency of del(13q), mutated IGHV status and no adverse aberrations (del(11q), del(17p), TP53 mutations).
|
27840426 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
In multivariable modeling considering age, gender, Rai stage, expression of ZAP70 or CD38, IGHV mutation status and FISH cytogenetics, only CLL-cell birth rate and IGHV mutation status met criteria for inclusion.
|
28115735 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Cell surface expression of CD150 and CD180 receptors in chronic lymphocytic leukemia (CLL) associates with mutational IGHV status and favourable prognosis.
|
28982149 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Relevant observations have been made in chronic lymphocytic leukemia (CLL), where gene mutations are distributed asymmetrically in cases bearing or not somatic hypermutations within the clonotypic immunoglobulin heavy chain variable region (IGHV) genes (e.g.
|
28892161 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
The immunoglobulin heavy-chain variable region gene (IgHV) mutational status is considered the gold standard of prognostication in chronic lymphocytic leukemia (CLL) and is currently determined by Sanger sequencing that allows the analysis of the major clone.
|
27795555 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
In this randomised, double-blind, phase 3 study (CLLM1; CLL Maintenance 1 of the German CLL Study Group), patients older than 18 years and diagnosed with immunophenotypically confirmed chronic lymphocytic leukaemia with active disease, who responded to chemoimmunotherapy 2-5 months after completion of first-line therapy and who were assessed as having a high risk for an early progression with at least a partial response after four or more cycles of first-line chemoimmunotherapy, were eligible if they had high minimal residual disease levels or intermediate levels combined with an unmutated IGHV gene status or TP53 alterations.
|
28916311 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
We devised a biomarkers-only CLL prognostic system based on the two most important prognostic parameters in CLL (i.e., IGHV mutational status and fluorescence in situ hybridization [FISH] cytogenetics), separating three different risk groups: (1) low-risk (mutated IGHV + no adverse FISH cytogenetics [del(17p), del(11q)]); (2) intermediate-risk (either unmutated IGHV or adverse FISH cytogenetics) and (3) high-risk (unmutated IGHV + adverse FISH cytogenetics).
|
28120419 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The RPPA investigation and its validation, identified 3 series of proteins: 1) molecules whose expression levels reached statistically significant differences in CLL vs. healthy controls (HSP70, Smac/DIABLO, cleaved PARP, and cleaved caspase-6); 2) proteins with a positive trend of difference in CLL vs. healthy controls (HS1, γ-tubulin, PKC α/β-II Thr-638/641, p38 MAPK Thr-180/Tyr-182, NF-κB Ser-536, Bcl2 Ser-70 and Src Tyr-527); and 3) molecules differentially expressed in patients with IGHV mutations vs. those without mutations (ZAP70, PKC-ζλ, Thr-410/403, and CD45).
|
27312846 |
2016 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Chromosomal aberrations, IGHV and TP53 mutation status are well-established and essential to discriminate between a more indolent course of disease and a high-risk CLL, which requires an alternative treatment regimen.
|
26890126 |
2016 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease.
|
26847028 |
2016 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
In this systematic review, we examined the role of immunoglobulin heavy-chain variable region gene (IGHV) mutation status and genetic abnormalities determined by interphase fluorescence in situ hybridization (FISH) in patients with newly diagnosed CLL.
|
26841802 |
2016 |